Replies to post #152482 on Biotech Values

[mcbio]

To my untrained eye, these look like very good results. I appreciate comments from the more knowledgeable posters about oncology drugs.

Would just say that the big caveat is they are comparing to historical control data; doesn't mean a whole lot until we get controlled data. On that note, I believe CLDX said we would get data in 2H13 from a controlled Phase 2 of rindo in recurrent glioblastoma in combo w/Avastin vs. Avastin+KLH control. Think this is where we get an initial true read on the drug's activity.

[biomaven0]

These historical comparisons are particularly difficult here because there is a substantial delay after diagnosis and surgery before the drug is actually administered. So the question is whether their comparables are truly comparable or not - maybe they are, but you'd have to look at how they did this very carefully to be sure. Basically you want an ITT-type analysis starting at the comparable point in time.

(Imagine that a patient has surgery, and then suddenly deteriorates and they decide not to proceed with the drug. My guess is they wouldn't include that patient in their data, which means you have to exclude patients like that from the historical controls as well).

Peter